With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market.

Novo Nordisk A/S (NYSE:NVO) has made headlines recently by reporting an impressive 18% sales growth in the first half of 2025. This growth highlights the company's significant role in the global ...

Novo Nordisk A/S reported that its sales in the Diabetes and Obesity care segment rose by 16% in Danish kroner, reaching DKK 145.4 billion. This growth was significantly driven by the Obesity care ...

Novo Nordisk A/S innovation and growth continue to shine. Now, it has a partnership with GoodRX Holdings. Click for my ...

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

While fasting has become a popular trend, particularly for people who hope to lose weight, new UBC Okanagan research suggests ...